This episode features Dr. Anna Casu, Associate Investigator at Translational Research Institute - AdventHealth. Here, she discusses the work AdventHealth is doing with TZIELD, the first FDA approved drug that can delay the progression of Type 1 diabetes by up to three years in adults and up to eight years in children, how the screening and treatment work, what it takes to get a drug FDA approved, and more.
Summary
AdventHealth Investigator discusses TZIELD, the First FDA Approved Drug for Type 1 Diabetes
Introduction
Dr. Anna Casu, Associate Investigator at Translational Research Institute - AdventHealth, recently discussed the work AdventHealth is doing with TZIELD, the first FDA approved drug that can delay the progression of Type 1 diabetes. During the interview, she shared information about how the screening and treatment work, what it takes to get a drug FDA approved, and more.
About Dr. Anna Casu
Dr. Kasu is an associate investigator at the Advent Health Translational Research Institute and an endocrinologist by training. She was diagnosed with Type 1 diabetes at the age of six, which is why she has dedicated her research to finding a cure. Her research involves participating in Trial Net, a big consortium that recently led to the approval of a new type one diabetes drug. This drug is the first to delay the onset of Type 1 diabetes and can help improve the quality of life for those affected by it.
Research Focus
Dr. Kasu is a co-investigator in two US studies that look at the relationship between diabetes and pancreatic cancer and acute pancreatitis. Her big priority this year is to screen people at risk for type one diabetes and get them into studies or treatments.
Conclusion
Dr. Kasu's work is leading the way in diabetes research and treatment. The approval of TZIELD by the FDA is a major breakthrough, and the research being conducted at AdventHealth is paving the way for further advancements in the fight against type 1 diabetes. By screening people at risk, Dr. Kasu hopes to identify more potential treatments and ultimately find a cure for this devastating disease.
Note: This is an AI generated transcript, not edited by a staff writer and is solely intended for educational purposes. If you have any questions/concerns, reach out to podcasts@beckershealthcare.com
This episode aired on 01/15/2023 and can be listened here.
Subscribe to Beckers Healthcare Podcast here.